“This collaboration will strengthen our mission to increase access to the Rampart solution for those who are on the front lines performing interventional procedures requiring fluoroscopy," said Tom Livingston, Rampart IC president and CEO.
BIRMINGHAM, Ala. (PRWEB) February 22, 2023
Rampart IC, a Birmingham-based medical device company specializing in radiation shielding and orthopedic protection, announced a collaborative agreement with Boston Scientific Corporation, a leading medical device manufacturer, to expand access and promote the importance of radiation safety and orthopedic protection solutions to medical professionals. The companies will work together on sales program offerings for physicians who could benefit from the Rampart shielding technology.
Interventional cardiologists spend extended time in catheterization labs and, therefore, rank as the occupation with the highest level of radiation exposure in the world.1 These physicians often face debilitating injuries resulting from the 20-30-pound lead aprons traditionally worn to reduce radiation exposure,2 with nearly half reporting some form of orthopedic injury.3 The Rampart M1128, which is designed for procedures conducted by interventional cardiologists, electrophysiologists, interventional neurologists, and interventional radiologists, is a fully adjustable and portable system equipped with radiation-attenuating panels that have 1mm lead equivalency, creating a wide shielding area, protecting the physician and surrounding medical personnel. The electric device is easily configured and adjusted, allowing for subtle positioning to suit the body shape of the patient.
“We are honored to work with Boston Scientific, a global medical technology leader, to address a significant unmet need through the protection of more cath lab professionals from harmful radiation exposure,” said Tom Livingston, Rampart IC President and CEO. “This collaboration will strengthen our mission to increase access to the Rampart solution for those who are on the front lines performing interventional procedures requiring fluoroscopy.”
The Rampart IC system is already employed by several prominent American healthcare systems and prestigious university medical institutions. In addition, Rampart IC has signed distribution agreements in the Middle East, Asia, Europe and North America, providing its radiation shielding solution to healthcare professionals in 62 countries around the world.
“I’m very excited about the next generation of operators who are going to be able to work in a better environment both from an orthopedic and radiation standpoint,” said Dr. Bob Foster, Rampart IC Founder and Chief Medical Officer. “The 100-year-old solution of heavy aprons will soon become obsolete. Rampart will allow operators to perform at their best by addressing the challenges of wearing heavy lead and minimizing radiation exposure.”
Rampart IC gained ISO 13485 certification in 2021 to facilitate continued growth in the U.S. and international markets. Rampart IC will handle direct sales within the United States, but they are growing their distribution network for international markets.
In addition to its own international growth, Rampart IC has agreements to sell and distribute products in the United States for Fluke Corporation and Mavig GmbH, a leading provider of personal protective equipment used in hospitals and medical practices.
Learn more at rampartic.com.
1. Zakeri F, Hirobe T, Akbari K. Biological effects of the low–dose radiation exposure on interventional cardiologist. International atomic energy agency: Occ Med ( Lond) 2010;60(6): 464-9
2. Orme NM, Rihal CS, Gulati R, et al. Occupational health hazards of working in the interventional laboratory: a multisite case control study of physicians and allied staff. J Am Coll Cardiol 2015; 65: 820-6.
3. Klein LW, Tra Y, Garratt KN, et al. Society for Cardiovascular Angiography and Interventions. Occupational health hazards of interventional cardiologists in the current decade: Results of the 2014 SCAI membership survey. Catheter Cardiovasc Interv. 2015 Nov; 86(5):913-24.